RHUMBLINE ADVISERS - SYROS PHARMACEUTICALS INC ownership

SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 64 filers reported holding SYROS PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.9%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of SYROS PHARMACEUTICALS INC
ValueSharesWeighting
Q1 2022$76,000
-65.0%
63,865
-4.2%
0.00%
Q4 2021$217,000
-27.2%
66,658
-0.2%
0.00%
Q3 2021$298,000
-15.6%
66,771
+3.2%
0.00%
Q2 2021$353,000
+1.1%
64,715
+38.6%
0.00%
Q1 2021$349,000
-32.2%
46,698
-1.7%
0.00%
-100.0%
Q4 2020$515,000
+29.7%
47,483
+5.8%
0.00%0.0%
Q3 2020$397,000
-23.9%
44,893
-8.2%
0.00%0.0%
Q2 2020$522,000
+123.1%
48,922
+24.0%
0.00%
Q1 2020$234,000
-14.0%
39,449
+0.2%
0.00%
Q4 2019$272,000
-32.7%
39,386
+1.2%
0.00%
-100.0%
Q3 2019$404,000
+11.3%
38,927
-0.7%
0.00%0.0%
Q2 2019$363,000
+26.5%
39,197
+24.8%
0.00%0.0%
Q1 2019$287,000
+58.6%
31,401
-3.1%
0.00%
Q4 2018$181,000
-29.0%
32,406
+51.4%
0.00%
Q3 2018$255,000
+11.4%
21,411
-4.7%
0.00%
Q2 2018$229,000
+47.7%
22,472
+87.6%
0.00%
Q1 2018$155,000
+55.0%
11,978
+16.7%
0.00%
Q4 2017$100,000
-46.5%
10,263
-19.4%
0.00%
Q3 2017$187,000
-5.6%
12,734
+3.4%
0.00%
Q2 2017$198,00012,3170.00%
Other shareholders
SYROS PHARMACEUTICALS INC shareholders Q3 2019
NameSharesValueWeighting ↓
ARCH Venture Management, LLC 200,000$1,768,0008.83%
Samsara BioCapital, LLC 1,407,949$11,608,0003.24%
Flagship Pioneering Inc. 2,938,494$25,976,0000.72%
ARK Investment Management 11,212,506$99,119,0000.59%
Portolan Capital Management 450,861$3,986,0000.45%
Capital Impact Advisors, LLC 168,600$1,490,0000.44%
Nikko Asset Management Americas, Inc. 4,182,346$36,261,0000.32%
Sio Capital Management, LLC 166,780$1,474,0000.29%
Virtus ETF Advisers LLC 34,835$308,0000.16%
Artal Group S.A. 465,500$4,115,0000.10%
View complete list of SYROS PHARMACEUTICALS INC shareholders